Systemic Mastocytosis (SM)

SM is a clonal disorder characterized by accumulation of abnormal mast cells in bone marrow and other organs. Most patients harbor the KIT D816V mutation. SM spans indolent forms with mediator symptoms to aggressive disease with organ dysfunction (C-findings) and associated hematologic neoplasms (SM-AHN).

Symptoms

• Flushing, pruritus, urticaria, anaphylaxis
• GI symptoms: abdominal pain, diarrhea, nausea
• Bone pain, osteoporosis, pathologic fractures
• Liver/spleen enlargement, cytopenias, weight loss
• Neuropsychiatric symptoms (brain fog, mood changes)

Diagnosis

• Major criterion: multifocal clusters of mast cells in bone marrow or other organs
• Minor criteria: KIT D816V mutation, aberrant mast cell phenotype (CD25/CD2), tryptase >20 ng/mL, spindle-shaped mast cells
• WHO categories: indolent SM, smoldering SM, aggressive SM, SM-AHN, mast cell leukemia
• Baseline tryptase, bone density scan, imaging for organ involvement

Treatment Strategy

Mediator Symptom Control

• H1 antihistamines (non-sedating + sedating at night)
• H2 blockers, leukotriene antagonists
• Cromolyn sodium for GI symptoms
• Aspirin for flushing (if tolerated)
• Omalizumab for refractory anaphylaxis/mediator symptoms
• Carry epinephrine autoinjector

Targeted Therapy (Advanced SM or symptomatic indolent with refractory mediator issues)

• Midostaurin (multi-kinase inhibitor) for aggressive SM/SM-AHN
• Avapritinib (selective KIT inhibitor) approved for advanced SM; start at lower doses if severe cytopenias
• Cladribine, interferon-alpha for cytoreduction when TKIs not suitable
• Supportive care for cytopenias, transfusions, bisphosphonates/denosumab for bone disease

Monitoring

• Track tryptase levels, organ function (liver, spleen, bone marrow), bone density
• Watch for transformation to aggressive SM or mast cell leukemia
• Manage associated hematologic neoplasms in SM-AHN per disease-specific guidelines

Living with SM

• Identify triggers (temperature changes, alcohol, NSAIDs, infections); maintain diary
• Adopt low-histamine diet if noted triggers
• Educate family, schools, workplaces on anaphylaxis management
• Mental health support; unpredictable flares cause anxiety
• Regular dental care (some anesthesia agents trigger mast cell degranulation—pre-medicate as advised)

Complications

• Anaphylaxis, shock
• Osteoporosis, fractures
• Organ dysfunction (liver failure, malabsorption)
• Cytopenias, clonal evolution

Research & Future Directions

Next-gen KIT inhibitors, combinations with epigenetic agents, and targeted immunotherapies aim to deepen responses.

Experimental & Emerging Treatments

• Bezuclastinib & Other Selective KIT Inhibitors: Under trial for improved tolerability.
• Combo TKIs + Hypomethylating Agents: For SM-AHN with myeloid neoplasms.
• CAR-T or Bispecific Antibodies: Targeting mast-cell surface antigens in advanced cases.
• Digital Symptom Trackers: Wearables identifying early mediator release through skin temperature/Galvanic responses.

Track SM with Diagnoza.care

Master Trigger Awareness & Therapy Response – Log mediator symptoms, tryptase levels, bone density, TKIs, antihistamines, epinephrine use, GI symptoms, and specialist visits; capture side effects; and let the AI companion highlight patterns that predict flares or signal disease progression.

---

Medical Disclaimer: Informational only. Work with your hematologist/allergist for classification, KIT testing, mediator management, and targeted therapy decisions. Sources: World Health Organization, European Competence Network on Mastocytosis, American Society of Hematology